PTEN公司
角鲨烯单加氧酶
前列腺癌
癌症研究
癌症
生物
PI3K/AKT/mTOR通路
医学
内科学
信号转导
基因
细胞生物学
遗传学
生物合成
作者
Xun Shangguan,Zehua Ma,Minghao Yu,Jie Ding,Wei Xue,Jun Qi
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2022-06-29
卷期号:82 (17): 3032-3044
被引量:14
标识
DOI:10.1158/0008-5472.can-21-3822
摘要
Considering the dismal prognosis of castration-resistant prostate cancer (CRPC), it is critical to identify novel therapeutic targets in this disease. Malignant cells have metabolic dependencies distinct from their healthy counterparts, resulting in therapeutic vulnerabilities. Although PTEN and TP53 are the most frequently comutated or codeleted driver genes in lethal CRPC, the metabolic dependencies underlying PTEN/p53 deficiency-driven CRPC for therapeutic intervention remain largely elusive. In this study, PTEN/p53 deficient tumors were determined to be reliant on cholesterol metabolism. Moreover, PTEN/p53 deficiency transcriptionally upregulated squalene epoxidase (SQLE) via activation of sterol regulatory element-binding protein 2 (SREBP2). In addition, PTEN deficiency enhanced the protein stability of SQLE by inhibiting the PI3K/Akt/GSK3β-mediated proteasomal pathway. Consequently, SQLE increased cholesterol biosynthesis to facilitate tumor cell growth and survival. Pharmacologic blockade of SQLE with FR194738 profoundly suppressed the invasive program of CRPC. Collectively, these results demonstrate a synergistic relationship between SQLE and PTEN/p53 deficiency in CRPC development and progression. Therefore, pharmacologic interventions targeting SQLE may hold promise for the treatment of patients with CRPC.This study reveals PTEN and p53 deficiency confers a dependence on SQLE-mediated cholesterol metabolism, providing insights for new therapeutic strategies for treating castration-resistant prostate cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI